Brind.
  1. Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.
  2. Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.

AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.

4 reports, 3 independent Updated 00:00
Still developing
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.

Who's involved

What this event is mainly about
AstraZenecaBristol-Myers Squibb

How it developed

Newest first. Tap a step to see who reported it.
  1. Investor concerns surface regarding the potential merger between AstraZeneca and Bristol-Myers Squibb.1 source
  2. AstraZeneca sought a mega-merger with a US rival.1 source

Keep exploring

Part of

Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant. All 3 developments

Within Bristol Myers Squibb acquired Karuna Therapeutics, and Cristian Massacesi joined BMS as Chief Medical Officer after working at AstraZeneca.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
1 more outlet ran the same wire story